Understand the source comparison
Lose 30 Pounds with Peptides: Mechanism Comparison
The following table compares semaglutide and tirzepatide across key research parameters: | Peptide | Receptor Target | Half-Life | Standard Maintenance Dose | Mean Body Weight Reduction (Clinical Trials) | GI Side Effect Incidence | Bottom Line ||—|—|—|—|—|—||
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares semaglutide and tirzepatide across key research parameters:
- | Peptide | Receptor Target | Half-Life | Standard Maintenance Dose | Mean Body Weight Reduction (Clinical Trials) | GI Side Effect Incidence | Bottom Line ||—|—|—|—|—|—|| Semaglutide | GLP-1 agonist | ~7 days | 1.7–2.4mg weekly | 14.9% at 68 weeks (STEP-1) | 30–40% during titration | Proven single-target mechanism; lower cost; suitable for GI-sensitive subjects || Tirzepatide | Dual GLP-1/GIP agonist | ~5 days | 10–15mg weekly | 20.9% at 72 weeks (SURMOUNT-1) | 40–50% during titration | Superior fat oxidation through dual receptor action; higher nausea incidence but greater weight reduction || Liraglutide | GLP-1 agonist | ~13 hours | 3.0mg daily | 8.0% at 56 weeks (SCALE) | 25–35% during titration | Daily injection requirement limits compliance; outperformed by weekly alternatives |
- For subjects targeting 30-pound loss with baseline BMI above 30, tirzepatide demonstrates a clear advantage in clinical outcomes. Semaglutide remains the preferred option for cost-conscious research or subjects with prior GI intolerance to dual agonists.